Objectives: Published rates of reintervention after endovascular aneurysm repair (EVAR) range from 10% to 30%. We evaluated a single university center's experience with reinterventions in the context of trial and United States Food and Drug Administration (FDA)-approved devices.
rate) underwent reintervention with a mean aneurysm size of 5.9 6 1.2 cm. The median follow-up was 5 years, with an overall survival of 70.1%. Device specific details are outlined in the Table. Most patients (79.5%) underwent two or fewer reinterventions, 20.5% underwent three, and 7.9% underwent four. For all devices, the most common etiology of reintervention was type II endoleak (52.5%), followed by type I endoleak (18.2%), type III endoleak (9.5%), limb kink (7.3%), iliac occlusive disease (5.8%), endotension (1.5%), and other. The Fig compares etiol ogies between trial and FDA-approved devices. The overall mean time to the first reintervention was 2.3 6 2.5 years, and univariate Cox regression identified male gender (hazard ratio, 1.91; 95% confidence interval [CI], 1.17-3.10; P ¼ .010) and age at the time of EVAR (hazard ratio, 1.03; 95% CI, 1.01-1.05; P ¼ .006) as risk factors for time to first reintervention. Among all patients requiring reintervention, the mean number of reinterventions for trial devices was significantly greater than that for FDAapproved devices (2.18 vs 1.65; P ¼ .009). Trial devices requiring reintervention had a nearly three-fold increase in odds for the need for greater than two reinterventions (odds ratio, 2.88; 95% CI, 1.12-7.37; P ¼ .031). Trial device, etiology of reintervention, and type of reintervention were not predictive of the need for explant or mortality, but the number of reinterventions was significantly associated with the need for explant (odds ratio, 1.86; 95% CI, 1.17-2.96; P ¼ .009). EVAR device and the need for explant did not impact mortality.
Conclusions: Despite the rigorous nature of patient enrollment in clinical trials and the development of newer iterations of investigational devices, patients undergoing EVAR with trial devices are more likely to undergo a greater number of reinterventions compared to FDAapproved EVARs. Although mortality and the need for explant were not significantly associated with trial devices, the former finding points to an ethical duty to properly inform patients willing to partake in investigational device trials.
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Standard EVAR in Patients With
Methods: We performed a retrospective review of a prospectively maintained database for all patients undergoing elective EVAR for infrarenal abdominal aortic aneurysms at a single institution from 2001 to 2016. 
